# Bevacizumab vs Dacarbazine in Metastatic Melanoma

> **NCT01705392** · PHASE2 · TERMINATED · sponsor: **Haukeland University Hospital** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Malignant Melanoma
- Unresectable Malignant Melanoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Propranolol
- **DRUG:** Enalapril
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT01705392
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2017-02-20
- **Final completion:** 2017-02-20
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of financing of the study drug. Not sufficient financial support.
- **Last updated:** 2017-02-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01705392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01705392, "Bevacizumab vs Dacarbazine in Metastatic Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01705392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*